Advertisement
Home »

Risankizumab: Valuable Treatment Option for IL-17 Inhibitor Non-Responders

Mar 29, 2023

REFERENCES & ADDITIONAL READING

  1. Warren R. Efficacy and safety after 52 weeks in psoriasis patients switching to risankizumab after suboptimal response to secukinumab or ixekizumab. S025, AAD Annual Meeting 2023, 17–21 March, New Orleans.

ABOUT THE CONTRIBUTORS

Author

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement